Given these concerns regarding CVD safety, marketing authorization for romosozumab indicates previous myocardial infarction (MI) or stroke as contraindications, underlying the urgent need to understand the causal role of sclerostin lowering on CVD outcomes, thereby providing physicians and patients with more credible information when balancing the risks and benefits of treatment. Here, SOST is linked to Stroke.